, Volume 254, Issue 9, pp 1233-1237
Date: 02 Apr 2007

Revised diagnostic criteria for neuromyelitis optica (NMO)

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


We analyzed neuromyelitis optica (NMO) IgG in the serum or CSF samples from 46 patients with suspected NMO (28) and limited forms of NMO (18). One hundred and fifteen samples from multiple sclerosis (MS) patients were included as controls. The final clinical diagnosis after follow-up was 16 NMO, 12 MS, 11 transverse myelitis (TM) and seven recurrent optic neuritis (RON). NMO-IgG was detected in 62.5% of NMO, 50% of the recurrent longitudinally extensive TM, 14.3% of the RON but in none of the MS patients. The authors then compared the newly revised diagnostic criteria for NMO with the criteria published in 1999, in the 28 patients with suspected NMO. The revised criteria had higher specificity, and positive and negative predictive value (83.3% vs. 25%; 87.5% vs. 62.5; 83.3% vs. 75%), but slightly lower sensitivity (87.5% vs. 93.7%). Our study confirms NMO-IgG as a highly specific marker of NMO, and the usefulness of the revised diagnostic criteria in predicting a diagnosis of NMO.
Other members of the Spanish–Italian NMO study group are listed below: Spain: Hospital de Basurto, Bilbao (A. Antiguedad); Hospital Clínico San Carlos, Madrid (R. Arroyo; M. Bartolomé; V. de Las Heras); Hospital de Donostia, San Sebastián (A. López de Munain; J. Olascoaga); Hospital Josep Trueta, Girona (L. Ramió); Hospital Germans Trias i Pujol, Badalona (C. Ramo); Hospital La Fe, Valencia (I. Boscá, B. Casanova); Hospital “Rio Carrión” Palencia (AL. Guerrero); Hospital de Valme, Sevilla (RF. Bolaños); Hospital de Viladecans, Viladecans (A. Martínez-Yélamos); Hospital Virgen del Rocío, Sevilla (JL. Casado-Chocán; A. Uclés-Sánchez). Italy: Department of Neuroscience, University of Padua (V. Argentiero); Department of Neurology, Hospital of Treviso (M. Vianello).